长效药物传递技术和服务市场，全球按技术、剂型、输送分子类型、所用材料、分销管道和地区分類的分析和预测（2025-2035 年）

受长效药物输送解决方案的需求和采用不断增加的推动，全球长效药物输送技术和服务市场规模正在稳步增长。

这种扩展反映出人们越来越认识到长效药物传递系统是一种非常有效的治疗方法。这一增长的主要驱动因素包括慢性病盛行率的不断上升、长效药物传递技术的不断进步以及以患者为中心的医疗保健模式的更广泛转变。

创新配方和长效药物传输系统正在推动主要的市场力量，刺激策略联盟并吸引製药和技术部门之间的投资。这种合作对于提高长效药物输送系统的能力至关重要，最终可提高患者的依从性和治疗效果。然而，儘管监管障碍和成本问题等挑战依然存在，但在长效药物输送不断创新的推动下，整体市场仍呈现强劲成长。

市场扩张的机会很大，特别是在新兴地区，长效药物输送解决方案有望满足对先进治疗方案日益增长的需求。在医疗保健投资增加、基础设施改善以及对更有效的慢性病管理的需求日益增长的推动下，新兴经济体预计将在这一扩张中发挥关键作用。长效药物传递在肿瘤学、糖尿病和中枢神经神经病变等治疗领域的应用日益广泛，正在加速市场发展并扩大其在多个医疗保健领域的影响力。

随着长效药物传输产业的不断发展，那些利用生物技术和奈米技术进步，同时应对监管复杂性、成本障碍和配方扩充性等挑战的公司将占据有利地位，并获得长期成功。透过促进创新和建立策略伙伴关係，这些公司可以促进长效药物传输市场的持续成熟，确保更广泛的可及性、改善的患者治疗效果和永续成长。

本报告研究了全球长效药物输送技术和服务市场，概述了市场状况以及技术、剂型、输送分子类型、所用材料、分销管道、地理位置和参与市场的公司概况等趋势。

目录

执行摘要

研究范围

第 1 章全球长效药物传递技术与服务市场概述

• 市场展望
• 产业展望
• 市场动态

2. 全球长效药物传递技术与服务市场分析（按技术），百万美元，2024 年至 2035 年

• 长效注射剂
• 长效水凝胶
• 长效植入
• 长效微针
• 奈米晶体悬浮液

3. 全球长效药物传递技术与服务市场分析（以剂型），百万美元，2024 年至 2035 年

• 剂型摘要
• 长效注射剂
• 长效植入式
• 局部/经皮
• 阴道
• 其他的

4. 全球长效药物传递技术与服务市场分析（以输送分子类型），百万美元，2024 年至 2035 年

• 交付的分子类型摘要
• 小分子
• 生物製药
• 其他的

5. 全球长效药物传递技术与服务市场分析（按所用材料），百万美元，2024 年至 2035 年

• 所用材料摘要
• 聚合物基
• 非聚合物基

6. 全球长效药物传输技术和服务市场分析（按分销管道划分），百万美元，2024 年至 2035 年

• 分销管道摘要
• 医院药房
• 零售药局

7. 全球长效药物传递技术与服务市场分析（按地区），百万美元，2024 年至 2035 年

• 市场概况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

8. 全球长效药物传输技术和服务市场竞争基准化分析和公司概况

• 竞争性基准化分析
• 竞争格局
• 公司简介
  • Adare Pharma Solution
  • Alkemeres
  • AMW GmbH
  • Creative Biolabs
  • Delpor, Inc.
  • Durect Corporation
  • Integral Biosystems
  • Nanexa AB
  • Corium, LLC
  • Hanmi Pharm Co. Ltd.
  • Camurus AB
  • Heron Therapeutics, Inc.

Global Long-Acting Drug Delivery Technologies and Services Market Overview

The global long-acting drug delivery technologies and services market is experiencing steady growth, driven by rising demand and increasing adoption of long-acting drug delivery solutions. This expansion reflects the growing recognition of long-acting drug delivery systems as a highly effective approach to treatment. Key drivers of this growth include the increasing prevalence of chronic diseases, continuous advancements in long-acting drug delivery technologies, and a broader shift toward patient-centric healthcare models.

Innovative formulations and long-acting drug delivery systems are gaining significant traction in the market, attracting both investments and fostering strategic collaborations between pharmaceutical and technology sectors. These collaborations are critical in advancing the capabilities of long-acting drug delivery systems, ultimately leading to improved patient compliance and outcomes. However, challenges such as regulatory hurdles and concerns over cost remain, yet the overall market trajectory suggests strong growth, supported by ongoing innovation in long-acting drug delivery.

Opportunities for market expansion are particularly strong in emerging regions, where long-acting drug delivery solutions are poised to meet the growing demand for advanced treatment options. Developing economies are expected to play a pivotal role in this expansion, fuelled by increasing healthcare investments, improving infrastructure, and the rising need for more effective chronic disease management. The growing application of long-acting drug delivery in therapeutic areas such as oncology, diabetes, and central nervous system disorders is accelerating market development and broadening its reach across multiple healthcare sectors.

As the long-acting drug delivery industry continues to evolve, companies that successfully navigate the challenges of regulatory complexities, cost barriers, and formulation scalability, while leveraging advancements in biotechnology and nanotechnology, will be well-positioned for long-term success. By fostering innovation and cultivating strategic partnerships, these companies can contribute to the continued maturation of the long-acting drug delivery market, ensuring broader accessibility, improved patient outcomes, and sustainable growth.

Industry Impact

The impact of long-acting drug delivery technologies and services on the pharmaceutical and healthcare industries is substantial, shaping various aspects of patient care and treatment strategies. A key benefit lies in improving patient adherence, as these systems typically require less frequent dosing, minimizing missed doses and enhancing overall treatment effectiveness. By promoting better adherence, long-acting drug delivery solutions contribute to improved patient outcomes, elevating the quality of healthcare while potentially lowering costs associated with untreated or inadequately managed conditions.

Moreover, the market has driven a surge of innovation and collaboration within the pharmaceutical industry. Companies are increasingly investing in research and development to formulate novel drug delivery systems, fostering a competitive environment that emphasizes efficiency and patient-focused solutions. The rise of interdisciplinary partnerships among pharmaceutical scientists, engineers, and clinicians is accelerating the advancement of groundbreaking technologies that surpass conventional drug delivery methods.

Market Segmentation:

Segmentation 1: by Technique

• Long-Acting Injectables
• Long-Acting Hydrogels
• Long-Acting Implants
• Long-Acting Microneedles
• Nanocrystal Suspensions

Long-Acting Injectables to Dominate the Global Long-Acting Drug Delivery Technologies and Services Market (by Technique)

In FY2024, the long-acting injectables segment led the global long-acting drug delivery technologies and services market (by technique). The growing preference for injectable formulations is driven by their ability to ensure sustained drug release over an extended period, providing benefits such as fewer dosing requirements and improved patient adherence. This dominance is especially notable in therapeutic areas where maintaining a consistent and prolonged therapeutic effect is essential, including chronic diseases and specific mental health disorders.

Segmentation 2: by Dosage Form

• Injectables
• Implantable
• Topical/Transdermal
• Vaginal
• Other Dosage Forms

Injectables to Dominate the Global Long-Acting Drug Delivery Technologies and Services Market (by Dosage Form)

In FY2024, the injectables segment led the global long-acting drug delivery technologies and services market (by dosage form). Known for their ability to provide sustained and controlled drug release through injection, injectables are gaining traction across multiple therapeutic areas, significantly shaping the evolution of long-acting drug delivery solutions.

Segmentation 3: by Type of Molecule Delivered

• Small Molecules
• Biologics
• Other Molecules

Small Molecules to Dominate the Global Long-Acting Drug Delivery Technologies and Services Market (by Type of Molecule Delivered)

In FY2024, the small molecules segment dominated the global long-acting drug delivery technologies and services market (by type of molecule delivered). Due to their molecular size and structure, small molecules are at the forefront of this market, driven by their versatility, broad therapeutic applications, and continuous advancements in drug formulation technologies.

Segmentation 4: by Material Used

• Polymer Based
• Non-Polymer Based

Polymer Based to Dominate the Global Long-Acting Drug Delivery Technologies and Services Market (by Material Used)

In FY2024, the polymer-based segment led the global long-acting drug delivery technologies and services market by material used. This dominance highlights a strategic shift toward polymer utilization in developing long-acting drug delivery systems, driven by their versatility, biocompatibility, and effectiveness in modulating drug release profiles.

Segmentation 5: by Region

• North America
• Europe
• Asia-Pacific
• Rest-of-the-World

The Asia-Pacific (APAC) region is experiencing substantial growth in the long-acting drug delivery technologies and services market, driven by rising demand, technological innovations, and an evolving healthcare landscape. This expansion is fuelled by a combination of factors that are accelerating the adoption and development of long-acting drug delivery solutions across various therapeutic applications.

Recent Developments in the Global Long-Acting Drug Delivery Technologies and Services Market

• In August 2023, AMW GmbH expanded into new European and international markets with the release of its first Notified Body Opinion (NBO) report for the goserelin implant.
• In November 2023, AMW GmbH and AdhexPharma announced a strategic collaboration to advance transdermal delivery systems.
• In February 2023, Innocore Pharmaceuticals, a Dutch company specializing in polymer-based long-acting injectables, secured funding from the European Regional Development Fund to develop a biodegradable polymer-based microneedle array patch for simplified and effective vaccine administration.
• In March 2023, DelSiTech received approval to develop controlled and sustained-release injectables for a prophylactic HIV vaccine.

Demand - Drivers, Restraints, and Opportunities

Market Drivers:

• Growing adoption of sustained-release drugs and technologies: The growing adoption of sustained-release drugs and associated technologies is a major factor driving the expansion of the long-acting drug delivery technologies and services market. This trend signifies a shift toward the development of pharmaceutical solutions that provide extended therapeutic effects, minimizing the need for frequent dosing and enhancing patient adherence to treatment regimens.
• Advancements in long-acting drug delivery technologies

Market Restraints:

• Limitations of long-acting drug delivery technologies: The global long-acting drug delivery technologies and services market encounters challenges due to certain limitations inherent in these technologies, which can hinder their widespread adoption and growth. One significant drawback is the potential for a delayed onset of action, limiting their suitability for conditions that require immediate therapeutic effects.
• Regulatory challenges

Market Opportunities:

• Introduction of biologics and biosimilars compatibility in technologies: The ongoing development of long-acting drug delivery technologies compatible with biologics and biosimilars offers a promising opportunity for market expansion. These advancements have the potential to enhance treatment options across a wide range of therapeutic areas that depend on biologics and biosimilars, enabling more efficient, sustained drug release. By improving the stability, bioavailability, and patient adherence of these therapies, long-acting delivery systems can drive innovation in disease management and broaden the scope of biologic-based treatments.
• Advantages of long-acting drug delivery technologies

How can this report add value to an organization?

Workflow/Innovation Strategy: The long-acting drug delivery technologies and services market, categorized by technique, is segmented into various specialized methods, including long-acting injectables, long-acting hydrogels, long-acting implants, long-acting microneedles, and nanocrystal suspensions. Additionally, the study offers an in-depth analysis of the different types of molecules delivered and the materials used, providing a comprehensive understanding of the market landscape.

Growth/Marketing Strategy: The long-acting drug delivery technologies and services market includes a diverse range of products and solutions designed to prolong drug action. These technologies focus on enhancing patient adherence, minimizing dosing frequency, and optimizing therapeutic efficacy. The market encompasses various injectable drug delivery systems and services that enable sustained, controlled, or targeted drug release over an extended duration.

Competitive Strategy: The study analyses and profiles key players in the global long-acting drug delivery technologies and services market, including manufacturers engaged in new product launches, acquisitions, expansions, and strategic collaborations. Additionally, a detailed competitive benchmarking of market participants provides insights into their relative positioning, offering a clear view of the competitive landscape. Furthermore, an in-depth examination of strategic initiatives such as partnerships, agreements, and collaborations help identify untapped revenue opportunities within the market.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• The base year considered for the calculation of the market size is 2024. The historical year analysis has been done from FY2021 to FY2023, and the market size has been calculated for FY2024 and projected for the period 2025-2035.
• The geographical distribution of the market revenue is estimated to be the same as the company's net revenue distribution. All the numbers are adjusted to two digits after decimals for report presentation reasons. However, the real figures have been utilized for compound annual growth rate (CAGR) estimation. CAGR is calculated from 2025 to 2035.
• The market has been mapped based on different types of products available in the market and based on several indications. All the key manufacturing companies that have a significant number of offerings to the long-acting drug delivery technologies and services market have been considered and profiled in the report.
• In the study, the primary respondent's verification has been considered to finalize the estimated market for the long-acting drug delivery technologies and services market.
• The latest annual reports of each market player have been taken into consideration for market revenue calculation.
• Market strategies and developments of key players have been considered for the calculation of sub-segment split.
• The base currency considered for the market analysis is US$. Currencies other than the US$ have been converted to the US$ for all statistical calculations, considering the average conversion rate for that particular year. The currency conversion rate has been taken from the historical exchange rate of the Oanda website or from the annual reports of the respective company if stated.

Primary Research

The key data points taken from the primary sources include:

• Validation and triangulation of all the numbers and graphs
• Validation of the report's segmentation and key qualitative findings
• Understanding of the numbers of the various markets for market type
• Percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• National Center for Biotechnology Information (NCBI), PubMed, Science Direct, World Bank Group, Organisation for Economic Co-operation and Development (OECD), Centers for Disease Control and Prevention (CDC), Global Burden Disease (GBD), and World Health Organization (WHO)
• Annual reports, SEC filings, and investor presentations of the leading market players
• Company websites and detailed study of their portfolio
• Gold standard magazines, journals, whitepapers, press releases, and news articles
• Databases

The key data points taken from the secondary sources include:

• Segmentations, split-ups, and percentage shares
• Data for market value
• Key industry trends of the top players in the market
• Qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• Quantitative data for mathematical and statistical calculation

Key Market Players and Competition Synopsis

The long-acting drug delivery technologies and services competition aims to accelerate pharmaceutical innovation by promoting the creation of novel, efficient, and patient-centric drug delivery solutions. By encouraging the exploration and adoption of long-acting technologies, the competition addresses significant challenges associated with conventional drug administration, including frequent dosing schedules and low patient adherence.

Globally, the long-acting drug delivery technologies and services market is experiencing robust growth, propelled by the rising prevalence of chronic diseases and continuous advancements in drug formulation and delivery mechanisms. Emphasizing patient-centred care and personalized medicine, these innovative solutions enhance convenience and treatment efficacy, thereby improving patient compliance and overall therapeutic outcomes.

Some of the prominent companies in this market are:

• Adare Pharma Solutions
• Alkermes
• AMW GmbH
• Corium, LLC.
• Creative Biolabs
• Delpor, Inc.
• Durect Corporation
• Hanmi Pharm
• Heron Therapeutics, Inc.
• Integral BioSystems
• Nanexa AB

Companies that are not a part of the aforementioned pool have been well-represented across different sections of the report (wherever applicable).

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Global Long-Acting Drug Delivery Technologies and Services Market Overview

• 1.1 Market Outlook
  • 1.1.1 Definitions
  • 1.1.2 Inclusion and Exclusion Criteria
  • 1.1.3 Market Size, 2024 - 2035 (US$)
  • 1.1.4 Market Footprint and Growth Potential
• 1.2 Industry Outlook
  • 1.2.1 Introduction
  • 1.2.2 Market Overview and Ecosystem
  • 1.2.3 Key Benefits of Long-Acting Drug Delivery Technologies and Services in Industries
  • 1.2.4 Current and Future State of Long-Acting Drug Delivery Technologies and Services
• 1.3 Market Dynamics
  • 1.3.1 Market Opportunities and Trends
  • 1.3.2 Market Drivers
    • 1.3.2.1 Impact Analysis
  • 1.3.3 Market Restraints
    • 1.3.3.1 Impact Analysis

2. Global Long-Acting Drug Delivery Technologies and Services Market Analysis (By Technology), $Million, 2024-2035

• 2.1 Long-Acting Injectables
• 2.2 Long-Acting Hydrogels
• 2.3 Long-Acting Implants
• 2.4 Long-Acting Microneedles
• 2.5 Nanocrystal Suspensions

3. Global Long-Acting Drug Delivery Technologies and Services Market Analysis (By Dosage Form), $Million, 2024-2035

• 3.1 Dosage Form Summary
• 3.2 Long-Acting Injectables
• 3.3 Long-Acting Implantable
• 3.4 Topical/Transdermal
• 3.5 Vaginal
• 3.6 Others

4. Global Long-Acting Drug Delivery Technologies and Services Market Analysis (By Type of Molecule Delivered), $Million, 2024-2035

• 4.1 Type of Molecule Delivered Summary
• 4.2 Small Molecules
• 4.3 Biologics
• 4.4 Other Molecules

5. Global Long-Acting Drug Delivery Technologies and Services Market Analysis (By Material Used), $Million, 2024-2035

• 5.1 Material Used Summary
• 5.2 Polymer-based
• 5.3 Non-Polymer-based

6. Global Long-Acting Drug Delivery Technologies and Services Market Analysis (By Distribution Channel), $Million, 2024-2035

• 6.1 Distribution Channel Summary
• 6.2 Hospital Pharmacies
• 6.3 Retail Pharmacies

7. Global Long-Acting Drug Delivery Technologies and Services Market Analysis (By Region), $Million, 2024-2035

• 7.1 Market Overview
  • 7.1.1 North America
    • 7.1.1.1 U.S.
    • 7.1.1.2 Canada
  • 7.1.2 Europe
    • 7.1.2.1 U.K.
    • 7.1.2.2 Germany
    • 7.1.2.3 France
    • 7.1.2.4 Italy
    • 7.1.2.5 Spain
    • 7.1.2.6 Rest of Europe
  • 7.1.3 Asia Pacific
    • 7.1.3.1 Japan
    • 7.1.3.2 China
    • 7.1.3.3 India
    • 7.1.3.4 Australia
    • 7.1.3.5 Rest of Asia Pacific
  • 7.1.4 Latin America
  • 7.1.5 Middle East & Africa

8. Global Long-Acting Drug Delivery Technologies and Services Market - Competitive Benchmarking and Company Profiles

• 8.1 Competitive Benchmarking
• 8.2 Competitive Landscape
  • 8.2.1 Key Strategies and Developments by Company
    • 8.2.1.1 Funding Activities
    • 8.2.1.2 Mergers and Acquisitions
    • 8.2.1.3 Regulatory Approvals
    • 8.2.1.4 Partnerships, Collaborations, and Business Expansions
  • 8.2.2 Key Developments Analysis
  • 8.2.3 Company Share Analysis/ Company Position Analysis
• 8.3 Company Profiles
  • 8.3.1 Adare Pharma Solution
    • 8.3.1.1 Overview
    • 8.3.1.2 Top Products/Product Portfolio
    • 8.3.1.3 Key Personnel
    • 8.3.1.4 Top Competitors
    • 8.3.1.5 Analyst View
  • 8.3.2 Alkemeres
    • 8.3.2.1 Overview
    • 8.3.2.2 Top Products/Product Portfolio
    • 8.3.2.3 Key Personnel
    • 8.3.2.4 Top Competitors
    • 8.3.2.5 Analyst View
  • 8.3.3 AMW GmbH
    • 8.3.3.1 Overview
    • 8.3.3.2 Top Products/Product Portfolio
    • 8.3.3.3 Key Personnel
    • 8.3.3.4 Top Competitors
    • 8.3.3.5 Analyst View
  • 8.3.4 Creative Biolabs
    • 8.3.4.1 Overview
    • 8.3.4.2 Top Products/Product Portfolio
    • 8.3.4.3 Key Personnel
    • 8.3.4.4 Top Competitors
    • 8.3.4.5 Analyst View
  • 8.3.5 Delpor, Inc.
    • 8.3.5.1 Overview
    • 8.3.5.2 Top Products/Product Portfolio
    • 8.3.5.3 Key Personnel
    • 8.3.5.4 Top Competitors
    • 8.3.5.5 Analyst View
  • 8.3.6 Durect Corporation
    • 8.3.6.1 Overview
    • 8.3.6.2 Top Products/Product Portfolio
    • 8.3.6.3 Key Personnel
    • 8.3.6.4 Top Competitors
    • 8.3.6.5 Analyst View
  • 8.3.7 Integral Biosystems
    • 8.3.7.1 Overview
    • 8.3.7.2 Top Products/Product Portfolio
    • 8.3.7.3 Key Personnel
    • 8.3.7.4 Top Competitors
    • 8.3.7.5 Analyst View
  • 8.3.8 Nanexa AB
    • 8.3.8.1 Overview
    • 8.3.8.2 Top Products/Product Portfolio
    • 8.3.8.3 Key Personnel
    • 8.3.8.4 Top Competitors
    • 8.3.8.5 Analyst View
  • 8.3.9 Corium, LLC
    • 8.3.9.1 Overview
    • 8.3.9.2 Top Products/Product Portfolio
    • 8.3.9.3 Key Personnel
    • 8.3.9.4 Top Competitors
    • 8.3.9.5 Analyst View
  • 8.3.10 Hanmi Pharm Co. Ltd.
    • 8.3.10.1 Overview
    • 8.3.10.2 Top Products/Product Portfolio
    • 8.3.10.3 Key Personnel
    • 8.3.10.4 Top Competitors
    • 8.3.10.5 Analyst View
  • 8.3.11 Camurus AB
    • 8.3.11.1 Overview
    • 8.3.11.2 Top Products/Product Portfolio
    • 8.3.11.3 Key Personnel
    • 8.3.11.4 Top Competitors
    • 8.3.11.5 Analyst View
  • 8.3.12 Heron Therapeutics, Inc.
    • 8.3.12.1 Overview
    • 8.3.12.2 Top Products/Product Portfolio
    • 8.3.12.3 Key Personnel
    • 8.3.12.4 Top Competitors
    • 8.3.12.5 Analyst View